Untreated Controls Preclinical injury models % reduction in healing time Tendon Transection (Rat Achilles model)50% Skin Wound Closure (Alkali burn model)45% Muscle Crush Injury (Rat quadriceps)40% Safety Data Safety Profile from Research What preclinical and early clinical studies report Preclinical Safety Summary LD50Not achieved Acute toxicityNone observed Chronic toxicityNone in 6-month studies Organ toxicityNone detected Human IV pilot (n=2)No adverse effects Cardiac/hepatic/renalNo effects detected Regulatory & Risk Considerations FDA statusUnapproved drug WADA statusBanned since 2022 (S0) Human trialsPhase 1 only Long-term effectsUnknown in humans Pro-angiogenic riskTheoretical unstudied Australia/NZPrescription only No lethal dose was reached in preclinical toxicology studies

In practical terms, this means a GHK-Cu peptide serum can sit comfortably in a skincare routine whether the brand is positioning itself as a science-driven anti-aging brand, a skin barrierfocused brand, or a premium dermatology-inspired skincare line
FIGURE 6 3.6 GHK-Cu promoted mucosal healing via inhibiting STAT3 activation To investigate the role of STAT3 activation in facilitating the therapeutic benefits of GHK-Cu, we meticulously designed and executed STAT3 knockdown experiments in vitro , utilizing the co-culture model
FDA Panel Votes to Recommend BPC-157 for Pharmacy Compounding A federal advisory panel voted on July 23, 2026 to recommend adding BPC-157 to the FDAs compounding list
#5 KPV Best for Inflammatory Arthritis and Autoimmune Joint Pain KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH)